FDA Approved: NUZYRA — Supplemental Application (Paratek Pharmaceuticals, Inc.)

View source ↗

Summary

FDA's supplemental application for NUZYRA (omadacycline) submitted by Paratek Pharmaceuticals, Inc., with the submission status indicated as AP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin and Skin Structure Infections
• Community-acquired Pneumonia

Drugs mentioned

• Nuzyra (Omadacycline)

Snippet

SUPPL AP for NUZYRA (OMADACYCLINE)